Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate in Myotonic Dystrophy Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults~* Epworth score ≥ 10~* Diagnosis of myotonic dystrophy type 1~Exclusion Criteria:~* hypersensibility to methylphenidate~* Pregnancy~* Patients who receive drugs that interfere with methylphenidate~* Cognitive impairment~* Sleep apnea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Methylphenidate versus baseline (Type: PLACEBO_COMPARATOR): None
- Arm 2: Placebo versus baseline (Type: PLACEBO_COMPARATOR): One table placebo per day during 3 week

Based on this trial design, predict the completion outcome and termination type (if applicable).